Clara D. Bloomfield, MD is a Distinguished University Professor at The Ohio State University (OSU) and holder of the William Greenville Pace III Endowed Chair in Cancer Research. Dr. Bloomfield is an internationally recognized clinical scientist whose over 45 years of ground breaking research on adult leukemia and lymphoma, described in over 1080 publications, have changed the way we think about these diseases and treat these patients. The recipient of many prestigious honors, Dr. Bloomfield is an elected member of the Institute of Medicine of the National Academy of Sciences and of the American Academy of Arts & Sciences.
Leukemia, Myeloid, Acute, Leukemia, Cancer, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Chromosome Aberrations, Lymphoma, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Trisomy, Leukemia, Promyelocytic, Acute
Gyongyi Szabo, MD, PhD is the Worcester Foundation for Biomedical Research Endowed Chair, Professor and Vice Chair of Medicine and Associate Provost at the University of Massachusetts Medical School. She is an internationally recognized leader in the field of liver immunology and inflammation. Her clinical investigations focus on alcoholic hepatitis, non-alcoholic fatty liver disease and viral hepatitis, and her laboratory studies molecular mechanisms of inflammation and innate immunity in liver injury to identify therapeutic targets in liver diseases. She is an expert in Toll-like and Nod-like receptor signaling pathways in alcoholic and non-alcoholic liver diseases. Her investigations recently revealed the importance of micro-RNAs and extracellular vesicles in liver diseases. She is a member of the Hungarian Academy of Sciences, Editor-in-Chief of Hepatology Communications, serves on Advisory Boards for NIH and several leading academic institutions, and is Immediate Past President of the American Association for the Study of Liver Diseases (AASLD).
Professor Vincent Njar completed his B. Sc. in Chemistry at University of Ibadan (the top University in Nigeria) in 1976 and went on to obtain a Ph.D. in Organic Chemistry in 1980 from University College London/University of London, (UK) under the supervision of Derek V. Banthorpe. Following two years of postdoctoral research with the late Eliahu Caspi at Worcester Foundation for Experimental Biology, Shrewsbury, Mass. (USA), he joined the Department of Chemistry at the University of Ibadan (Nigeria) as Lecturer II. He was promoted through the ranks and became Professor of Organic Chemistry in 1996. During his tenure at University of Ibadan, he was visiting Professor at several institutions, including: Johns Hopkins University, Baltimore, USA (1988, 1989, 1992 & 1993); Universite de Sherbrooke, Sherbrooke, Quebec, Canada (1990); University of Southampton, Southampton, UK (1991, 1992 & 1995); and University of Saarland, Saarbruecken, Germany (1994-1995). Following several research visits from 1996 to 1998 collaborating with the late Dr. Angela Brodie at University of Maryland School of Medicine, Baltimore (UMSOM), internationally renowned breast and prostate cancer researcher, he immigrated to the US in 1999. He is currently Professor of Medicinal Chemistry and Pharmacology, Department of Pharmacology and Head, Medicinal Chemistry Section of Center for Biomolecular Therapeutics (CBT), University of Maryland School of Medicine, Baltimore, MD, USA. Professor Njar has published >120 articles, reviews and book chapters and is the lead inventor on over 50 issued patents and pending patent applications. On 85% of these, he is first or senior/corresponding author. Professor Njar actively participates in several drug discovery and development grant review committees nationally and internationally. His research is currently supported by the US National Institutes of Health (NIH) and the National Cancer Institute (NCI). He is co-founder of Isoprene Pharmaceuticals Inc., a company focused on the development of therapies for oncology and dermatological diseases.
Dr. Shevchenko is the Chairman of the WAMS International Board of Biotechnology/Medical Technology, Executive Board Member of the WAMS International Medical Research Council (IMREC), Chairman of the WAMS Ukrainian Committee, Fellow of the Academy & Member of the WAMS Executive Council (WAMS Executive Board), and Academy Professor of Medicine at WAMS. Dr. Shevchenko has a MSc degree in Biochemistry and Molecular Biology at the Botany Institute of the Ukrainian Academy of Sciences, he is Doctor of Medicine from the Kharkov National Medical University. In 1990, together with Prof. Sjoerd Bulstr, Dr. Shevchenko initiated the Dutch - Ukrainian Program on Orthopaedic Devices and Biomaterials in Maastrict, Netherlands.
Dr. Shevchenko combines his vision in translational medical science for therapeutics with extraordinarily moral values and ethics. By pushing cutting-edge biotechnology solutions with the goal of redefining how complex medical situations are treated, Dr. Shevchenko guides us as a true hero and leader at the World Academy of Medical Sciences. It is my honor to learn from him and support him on his current and future projects, as we aim to create a better world, as brothers. He has my respect and admiration always.
Shaoguang Li obtained his PhD degree from Tulane University, USA, and did his postdoctoral studies at Harvard Medical School. He is currently a professor at University of Massachusetts Medical School, USA. He has published some seminal work related to leukemia stem cells in highly competitive journals such as Nature Genetics, JCI, PNAS, Blood, Leukemia, etc.
Medicinal Chemistry, oncopharmacology, anti-cancer drug discovery and development, small-molecule design and synthesis, cancers (breast, prostate, pancrease, skin), steroidal compounds, retinoidal compounds, steroid and retinoid-mimetics, pharmacokinetics, anti-tumor xenograft studies, inhibitors of CYP26, CYP17 and CYP19 (aromatase), AR antagonists, AR/AR-Vs degraders, Mnk1/2 degraders, inhibitors of oncogenic protein translation, Mnk1/2, eukaryotic translation initiation factor 4F/ eukaryotic initiation factor 4E, inhibitors of tumor growth and metastasis, mechanisms of action of anti-cancer agents.